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Idiosyncratic drug-induced liver injury (iDILI) is a major cause of acute liver failure
resulting in liver transplantation or death. Prediction and diagnosis of iDILI remain a
great challenge, as current models provide unsatisfying results in terms of sensitivity,
specificity, and prognostic value. The absence of appropriate tools for iDILI detection
also impairs the development of reliable biomarkers. Here, we report on a new
method for identification of drug-specific biomarkers. We combined the advantages of
monocyte-derived hepatocyte-like (MH) cells, able to mimic individual characteristics,
with those of a novel mass spectrometry-based proteomics technology to assess
potential biomarkers for Diclofenac-induced DILI. We found over 2,700 proteins
differentially regulated in MH cells derived from individual patients. Herefrom, we
identified integrin beta 3 (ITGB3) to be specifically upregulated in Diclofenac-treated MH
cells from Diclofenac-DILI patients compared to control groups. Finally, we validated
ITGB3 by flow cytometry analysis of whole blood and histological staining of liver
biopsies derived from patients diagnosed with Diclofenac-DILI. In summary, our results
show that biomarker candidates can be identified by proteomics analysis of MH cells.
Application of this method to a broader range of drugs in the future will exploit its
full potential for the development of drug-specific biomarkers. Data are available via
ProteomeXchange with identifier PXD008918.
Keywords: DILI, biomarker, proteomics, drug-development, monocyte-derived hepatocyte-like cells
Abbreviations: ALI, acute liver injury; ALT, alanine aminotransferase; APAP, acetaminophen; AST, aspartate
aminotransferase; BSA, bovine serum albumin; ITGB3, integrin beta 3; DILI, drug-induced liver injury; DILIN, drug-
induced liver injury network; DMSO, dimethylsulfoxide; EDTA, ethylenediaminetetraacetic acid; EMA, European Medicines
Agency; FDA, Food and Drug Administration; HMGB1, high-mobility group box-1; iDILI, idiosyncratic drug-induced liver
injury; IMI, innovative medicines initiative; Lys-C, endoproteinase Lys-C; MCSFR1, macrophage stimulating factor receptor
1; MH cells, monocyte-derived hepatocyte-like cells; MS, mass spectrometry; NSAID, nonsteroidal anti-inflammatory drug;
PCA, principal component analysis; ROC, receiver operating characteristic; RUCAM, Roussel Uclaf Causality Assessment
Method; SDC, sodium deoxycholate.
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INTRODUCTION
Drug-induced liver injury is the leading cause for acute liver
failure in United States and Europe (Kullak-Ublick et al., 2017).
Toxic reactions due to drug intake can be dose-dependent,
as in the case of APAP ingestion and are termed “intrinsic
DILI.” In contrast, iDILI affects only susceptible patients,
and even though it is a rare event (1:10,000 to 1:100,000
per drug), it often results in death or liver transplantation
(Bell and Chalasani, 2009). Preclinical models usually fail to
predict iDILI (Atienzar et al., 2016) and thus, iDILI is often
being detected only after market approval. Even then, iDILI
diagnosis remains a diagnosis of exclusion after elimination
of other etiologies for liver damage (e.g., viral infections such
as hepatitis or autoimmune diseases). Consequently, iDILI
diagnosis is incorrect in up to 25% of the cases (Teschke et al.,
2014). Moreover, current causality assessment methods, such
as the RUCAM score and expert opinion encounter difficulties
in identifying the causative drug in polymedicated patients
(Andrade et al., 2009; Anderson and Borlak, 2011; Teschke
and Eickhoff, 2016). While both methods have their strengths,
they both heavily rely on a comprehensive collection of data
requiring extensive investigations and documentation of the
course of disease (Danan and Teschke, 2016). Additionally,
both methods require an experienced investigator to perform
optimally. Since DILI is still a diagnosis of exclusion, correct
causality assessment is time consuming and expensive (Hayashi,
2016).
The lack of a reliable in vitro diagnostic tool for iDILI also
impairs the development of safety biomarkers, as false positive
or false negative diagnosis impair the identification of specific
biomarkers (Teschke et al., 2017). Thus, several attempts to
develop safety biomarkers for iDILI provided unsatisfying results
because of low predictive values (Singer et al., 2010; Spraggs
et al., 2011). Since iDILI is a rare event, this may in part results
from dilution caused by false positives in the suspected iDILI
groups. Several promising biomarker candidates have recently
been proposed, e.g., HMGB1, MCSFR1, cytokeratin 18, and
micro-RNAs miR-122 and miR-192 (Robles-Díaz et al., 2016).
However, some limitations exist: the majority of these markers
are not liver specific (HMGB1, cytokeratin 18, and MCSFR1),
and even if they specifically detect liver damage, the issue of
causality remains the most pressing challenge. Moreover, none
of these candidates has been shown to be drug-specific, which
would be an important advantage in improving drug safety
(Andrade et al., 2009). Thus, there is currently no valid diagnostic
or prognostic biomarker available for iDILI (Teschke et al.,
2017).
We have previously reported on the development of the
first in vitro test able to diagnose iDILI using a blood sample
from respective patients with iDILI suspicion. The test is
based on the generation of MH cells, which reflect individual
donor characteristics, such as toxic reactions to drug treatment
(Benesic et al., 2012). This test is able to distinguish iDILI from
other causes of liver damage and furthermore, to identify the
culprit drug in polymedicated patients (Benesic et al., 2016,
2018; Benesic and Gerbes, 2018). In the current study, we
combine the ability of MH cells to simulate specific toxic
reactions in samples from individual donors with a new and
improved proteomics technology in order to identify drug-
specific biomarkers for iDILI (Kulak et al., 2014). Here, we
focus on Diclofenac-DILI, since Diclofenac is the worldwide
most prescribed NSAID (Altman et al., 2015) and is the most
frequently implicated agent in DILI caused by NSAIDs (Fontana
et al., 2009; Björnsson, 2016; Schmeltzer et al., 2016). Diclofenac-
DILI displays a well characterized drug signature which allows
accurate diagnosis by clinical assessment methods such as
RUCAM (Boelsterli, 2003). Moreover, the injury mechanisms
of Diclofenac are well described, involving both metabolic cell
pathways and immunologic reactions (Boelsterli, 2003). Thus,
our goal was to investigate whether Diclofenac-treatment of
MH cells generated from patients clinically diagnosed with
Diclofenac-DILI results in different protein expression patterns
compared to vehicle control and to other control groups,
respectively.
MATERIALS AND METHODS
Patients and Causality Assessment
Subjects without liver damage and patients presenting with
ALI and iDILI suspicion were included in this study. DILI
was diagnosed by clinical causality assessment, according to
previously published criteria (Benesic et al., 2016; see also
Supplementary Table S1) as well as RUCAM (Danan and
Teschke, 2016).The resulting classifications were “definite,”
“highly likely,” or “probable” for iDILI and “possible” or
“unlikely” for other ALI (liver injury due to other causes than
iDILI). Informations on subjects and patients are presented in
Supplementary Tables S2, S3.
Cell Culture
Monocyte-derived hepatocyte-like cells were generated by
gradient centrifugation and adherence separation of peripheral
blood monocytes and cultured as described in Benesic et al.
(2012). For toxicity testing, freshly generated MH cells were
treated with 100 µM Diclofenac for 48 h (optimal concentration
was determined by dose–response curves in 25 donors –
unpublished data), followed by toxicity measurements, as
described elsewhere (Benesic et al., 2016). In brief, following
cell exposure to Diclofenac or vehicle, lactate dehydrogenase
(LDH) was measured by optical density using the Promega
Cytotox non-radioactive Assay R© (Promega, Mannheim,
Germany) from supernatants and cell lysates after lysis
with 0.1% TWEEN in MOPS buffered saline. Each condition
was tested in triplicate. LDH release was calculated from
ODsupernatant: (ODsupernatant + ODlysate). MH cell test
results were considered as positive when increase in LDH-
release exceeded the fourfold standard deviation of vehicle
control. For proteomics analysis, cryoconserved MH cells
were thawed and treated with 100 µM Diclofenac or vehicle
(DMSO) for 48 h, followed by sample preparation for proteomics
analysis.
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Proteomics Analysis
Sample preparation was performed as described previously
(Kulak et al., 2014). For each condition, three biological replicates
were used. Briefly, 50,000 MH cells were lysed, denatured,
reduced, and alkylated in SDC buffer for 10 min at 95◦C.
Proteins were digested with Trypsin and LysC (1:100 w/w)
at 37◦C for 3 h. Acidified peptides were purified using SDB-
RPS StageTips. Eluted peptides were completely dried using
a SpeedVac centrifuge and suspended in LC loading buffer.
Peptides were separated on a reverse phase column (50 cm length,
75 µm inner diameter) packed in-house with ReproSil-Pur C18-
AQ 1.9 µm resin (Dr. Maisch GmbH, Ammerbuch, Germany).
Reverse-phase chromatography was performed with an EASY-
nLC 1000 ultrahigh pressure system, coupled to a Q-Exactive
HF Mass Spectrometer (Thermo Scientific). Peptides were loaded
with buffer A (0.1% (v/v) formic acid) and eluted with a nonlinear
100-min gradient of 5–60% buffer B (0.1% (v/v) formic acid,
80% (v/v) acetonitrile) at a flow rate of 250 nL/min. After each
gradient, the column was washed with 95% buffer B and re-
equilibrated with buffer A. Column temperature was kept at 50◦C
by an in-house designed oven with a Peltier element. Operational
parameters were real-time monitored by the SprayQC software
(Scheltema and Mann, 2012). Raw files were analyzed by
MaxQuant software (version 1.5.3.2) (Cox and Mann, 2008) and
peak lists were searched against theHomo sapiensUniprot FASTA
database (Version 2014/4) and a common contaminants database
(247 entries) by the Andromeda search engine (Cox et al., 2011).
Label-free quantification was done using the MaxLFQ algorithm
(Cox et al., 2014) integrated into MaxQuant. Data was analyzed
by using the Perseus software (Tyanova et al., 2016). Positions
containing non-valid values were filtered out in order to obtain
a protein data set present in all samples. Means and standard
deviations were calculated from the remaining data and groups
according to the study subjects were annotated. In addition,
the annotations contained information on vehicle (baseline) or
Diclofenac treatment (treated) of the respective MH cells. The
data were log2-transformed and normalized using the Z-score
function of the Perseus software. The MS proteomics data have
been deposited to the ProteomeXchange Consortium via the
PRIDE (Kullak-Ublick et al., 2017) partner repository with the
data set identifier PXD008918.
Flow Cytometry Analysis
Ethylenediaminetetraacetic acid-blood was diluted 1:2 in PBS
0.5% BSA and stained with 5 µL of anti-ITGB3 (#564174; BD
Biosciences) or anti-IgG (#554681; BD Biosciences) for 45 min
on ice. Samples were then washed twice, followed by erythrocyte
lysis (lysis solution: 1.5 M NH4Cl, 0.1 M KHCO3, 1 mM EDTA
disodium salt, in double distilled water) for 7–10 min at room
temperature. Samples were then centrifuged, the cell pellet was
resuspended in PBS 0.5% BSA and analyzed for ITGB3 expression
using a BD Accuri flow cytometer (BD Biosciences).
Immunohistochemistry
Liver samples for immunohistochemical analyses were selected
from the tissue archives of the Institute of Pathology, Ludwig
Maximilian University of Munich, Germany. Liver samples
originated from patients with clinical indication for liver
biopsy. Tissue sections were stained with anti-ITGB3
(Ventana) on an automated slide staining platform from
Ventana, according to manufacturer’s instructions. For analysis,
representative brightfield images were taken on a Leica DMD
108 microscope at the indicated magnifications. ITGB3-positive
infiltration spots at inflammation sites were counted at 40×
magnification.
Statistics
Data analysis and statistics for proteomics data including
PCA, Heat Map, hierarchical clustering were performed by
Perseus software (Tyanova et al., 2016). The “proteinGroups.txt”
file produced by MaxQuant was further analyzed in Perseus
(version 1.5.1.6). PCA was done on the logarithmized LFQ
intensities of all single-shot runs. Unsupervised hierarchical
clustering of significantly (ANOVA, FDR < 0.05) regulated
proteins (z-scored MaxLFQ values) was performed in Perseus.
Data from FACS-analysis and immunohistochemistry were
analyzed using SPSS-software (IBM SPSS Statistics 25.0). After
testing for normal distribution Student’s t-test or Kruskal–
Wallis test were applied. Where applicable the Chi-Square
test was applied. Results were considered significant when
p< 0.05.
RESULTS
We included in our study six healthy subjects and 16 patients
presenting with liver injury, initially suspected of iDILI. We
further divided these subjects into two groups: one that had
previously ingested Diclofenac (Diclo) and one which had
never been exposed to Diclofenac before (Control), as a
negative control (Table 1). Patients with liver injury were
diagnosed based on clinical causality assessment (Supplementary
Tables S1, S2) including RUCAM. This resulted in the
following subgroups: patients suffering from iDILI due to
Diclofenac (DicloDILI), patients suffering from iDILI due to
other drugs (Diclo_otherDILI and Control_otherDILI) and
patients suffering from liver injury due to other causes than
iDILI (Diclo_otherALI and Control_otherALI) (Figure 1A and
Supplementary Table S2). Subjects without liver injury were
named Diclo_tolerator if they have been exposed to Diclofenac
without resulting liver injury and Control_healthy if there was
no Diclofenac exposure in the history. Importantly, all DicloDILI
patients had a causality likelihood of at least “highly likely” for
iDILI due to Diclofenac. In parallel to causality assessment, we
generated MH cells from blood samples of each subject and used
them for toxicity testing (MH cell test) and proteomics analysis
(Figures 1B,C). The MH cell test was positive for Diclofenac
only in DicloDILI patients, whereas co-medications in these
patients tested negative (Supplementary Table S2). These results
confirmed the previously reported ability of MH cells to mirror
individual drug response (Benesic et al., 2016).
Mass spectrometry-based proteomics analysis of MH cells
from the individual patients identified more than 2,700 proteins
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TABLE 1 | Study subjects.
Diclofenac exposure Yes No Comment
DILI due to Diclofenac 4 (DicloDILI) n.a. Patients with DILI due to Diclofenac
Healthy 3 (Diclo_tolerator) 3 (Control_healthy) Subjects without signs of liver injury
DILI due to another drug 2 (Diclo_otherDILI) 4 (Control_otherDILI) Patients with DILI due to another drug
Other ALI 3 (Diclo_otherALI) 3 (Control_otherALI) Patients with acute liver injury of non-drug cause
Total 12 10 Total subjects: 22
MH cells for proteomics analysis were obtained from 22 subjects: 12 patients exposed to Diclofenac of whom four had DILI due to Diclofenac (DicloDILI), three had
tolerated Diclofenac without signs of liver injury (Diclo_tolerator), two had DILI due to another drug but were concomitantly treated with Diclofenac (Diclo_otherDILI), and
three were exposed to Diclofenac but had acute liver injury due to a non-drug cause (Diclo_otherALI). Another 10 patients were never exposed to Diclofenac, of whom
three had no signs of liver injury (Control_healthy), four had DILI due to a drug other than Diclofenac (Control_otherDILI), and three had acute liver injury due to a non-drug
cause (Control_otherALI).
expressed in all subject groups. Hierarchical clustering of this
data set revealed considerable differences in protein expression
between sample groups (Figures 2A,B and Supplementary
Figure S1). As shown by the heat map diagram, DicloDILI
specimens built a separate cluster compared to the other groups,
independently of Diclofenac-treatment (vertical clustering in
Figure 2A). Thus DicloDILI specimens clustered furthest
away from samples of healthy/exposed subjects, which had
received and tolerated Diclofenac. These observations were
confirmed by PCA, showing that the proteome of untreated
MH cells from DicloDILI patients (DicloDILI_baseline) display
a unique signature compared to all other subject groups (termed
“other_baseline”) (Figure 2B and Supplementary Figure S1).
Moreover, protein expression in MH cells from DicloDILI
patients showed a distinct shift after Diclofenac-treatment
compared to vehicle control (DicloDILI_treated). In contrast,
Diclofenac-treatment failed to induce substantial changes to
protein expression in MH cells derived from nonDicloDILI
subjects (other_treated; Figure 2B). Furthermore, hierarchical
clustering identified two main protein expression clusters
(horizontal clustering in Figure 2A): one that is predominantly
downregulated in DicloDILI (turquois) and one that is mainly
upregulated in DicloDILI (red). This distinct regulation pattern
was only present in DicloDILI specimens and not in the other
groups. Together with the results of the PCA analysis, this
suggests that differences in the proteome of MH cells could reflect
individual susceptibility to Diclofenac-DILI.
Since Diclofenac caused toxic responses only in MH cells of
patients with Diclofenac-DILI and downregulation of proteins
may be due to cytotoxicity, we focused on the protein
cluster predominantly upregulated in DicloDILI (rectangle in
Figure 2A) as a source of potential drug specific biomarkers.
Therefore, we performed pathway enrichment analysis to reveal
main biological mechanisms underlying DILI by Diclofenac
FIGURE 1 | Experimental design. (A) Generation of MH cells followed by proteomics analysis and toxicity testing in parallel and (B) protocol for MH cell treatment
prior to proteomics analysis. Brightfield images are shown for illustrative purposes only.
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FIGURE 2 | Proteomics analysis of MH cells identifies differentially regulated proteins in the investigated subject groups. (A) Hierarchical clustering of the different
sample groups, treated with vehicle (–) or Diclofenac (+). Vertical clustering displays similarities between sample groups, while horizontal clusters reveal differentially
regulated protein groups. The upregulated protein cluster marked by the dotted rectangle was further assessed for pathway enrichment, as displayed in (C).
(B) Principal component analysis of protein expression in MH cells treated with either vehicle (baseline) or 100 µM Diclofenac (treated). MH cells of DicloDILI patients
were compared to all other groups (Diclo_tolerator, Diclo_otherALI, Diclo_otherDILI, Control_healthy, Control_otherALI, and Control_otherDILI), grouped under the
term “other.” (C) Pathway enrichment analysis within the protein cluster mainly upregulated in DicloDILI (dotted rectangle from A).
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FIGURE 3 | Diclofenac-DILI patients express lower levels of ITGB3 compared to control subjects. (A) Histogram plots of erythrocyte-lysed whole blood samples
from three DicloDILI patients and one healthy subject, analyzed by flow cytometry for ITGB3 expression. In red: percentage of ITGB3-positive cells. (B) Distribution of
ITGB3 values among subjects from each group. n = 3 for healthy, n = 7 for other ALI, n = 13 for other DILI, and n = 3 for DicloDILI. Red dotted line: threshold (= 60%)
determined by receiver operating characteristic (ROC) analysis and used to discriminate between ITGB3-positive and ITGB3-negative samples. ∗p < 0.05.
(Figure 2C). Thus, we identified five signaling pathways, which
were significantly upregulated in DicloDILI upon Diclofenac
exposure (Figure 2C and Supplementary Table S4).
In order to identify specific biomarkers for Diclofenac-
DILI, we searched for proteins that were upregulated upon
Diclofenac-treatment exclusively in MH cells from DicloDILI
patients and not in the other groups. Additionally, the
potential biomarker should be easy to detect, e.g., from a
blood sample, to facilitate clinical application. Under the
top 10 upregulated proteins in MH cells from DicloDILI
patients, only one membrane protein met these criteria: ITGB3,
which was fourfold upregulated in the DicloDILI condition
upon Diclofenac-treatment, in contrast to the other groups
(Supplementary Table S5). In line with this finding, several
cell adhesion molecules were also enriched within the protein
cluster upregulated in DicloDILI (Figure 2C). ITGB3 is expressed
on peripheral blood cells (Luscinskas and Lawler, 1994; Harris
et al., 2000), which indicated that it can be measured in blood
samples.
Integrin beta 3 expression was determined by flow cytometry
analysis of erythrocyte depleted whole blood (Supplementary
Figure S2). Flow cytometry analysis of ITGB3 expression in
the different subject groups revealed that patients diagnosed
with Diclofenac-DILI displayed a reduction in the relative
amount of ITGB3-positive cells in whole blood compared to
other groups (Figures 3A,B). Based on the results of the ROC
analysis, we determined a threshold of 60% ITGB3-positive
cells in order to discriminate DicloDILI patients from other
subjects. Importantly, all values of DicloDILI patients were below
this threshold, while those of the other ALI and other DILI
subjects were above the threshold. We also observed a correlation
between the levels of ITGB3-positive cells and the course of
liver parameters (Supplementary Figure S3). Thus, DicloDILI2
displayed the lowest relative amount of ITGB3-positive cells,
and had the worst outcome, requiring liver transplantation. By
contrast, DicloDILI3 yielded the highest value for ITGB3 among
the DicloDILI group and recovered within a few weeks after the
initial liver injury and stopping of Diclofenac administration.
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FIGURE 4 | Immunohistochemical staining of liver biopsies with antibody against ITGB3. (A) Representative brightfield images of ITGB3 expression in liver biopsies
from the different patients (10× and 20×). Arrows indicate ITGB3-positive infiltrations. Diffuse brown areas represent unspecific staining. Scale bar: 100 µm.
(B) Relative quantification of ITGB3-positive infiltrations at inflammation sites (n = 18 for DicloDILI2, n = 17 for other ALI, and n = 24 for other DILI. ∗p < 0.05,
∗∗p < 0.005, whereas n represents the number of inflammatory sites per biopsy). (C) Schematic representation of the role of ITGB3 in Diclofenac-DILI. After initial
liver injury by Diclofenac, ITGB3-positive cells may be specifically recruited into the liver of susceptible patients and contribute to inflammation and liver damage.
We further investigated whether ITGB3 expression changes
with disease progression/remission. DicloDILI1 and DicloDILI2
were included in the study during the acute phase of the drug
reaction, also confirmed by strong elevation of the liver enzymes
ALT and AST (Supplementary Figures S3A,B). At this time point,
ITGB3 expression was below the determined threshold of 60%
(Supplementary Figures S3A,B). Closer monitoring of ITGB3
expression in DicloDILI1 and DicloDILI2 over a time period
revealed that ITGB3 correlated inversely with liver enzymes
(ALT and AST) and thus, with patient recovery (Supplementary
Figures S3A,B). These results suggest that ITGB3 might also
be used to monitor disease progression and possibly support
decision making for the need of medical interventions.
Finally, we searched for an explanation why ITGB3 is
upregulated in Diclofenac-treated MH cells from DicloDILI
patients, but downregulated in whole blood of the same
subject population. We postulated that ITGB3-positive cells
would be recruited from the peripheral blood into the liver
during Diclofenac-induced liver injury. To prove this theory,
we performed immunohistochemical staining for ITGB3 in liver
biopsies of DicloDILI2, one other ALI and one other DILI
patient. We observed an enhanced expression of ITGB3 for
DicloDILI2 compared to the other two samples, predominantly
at inflammation sites (Figure 4A). Quantification of ITGB3
expression at these sites revealed significant differences between
DicloDILI2 and other ALI/other DILI (Figure 4B).
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DISCUSSION
The need for specific DILI biomarkers is an international
acknowledged issue targeted by the EMA through the IMI
projects SAFE-T1 and MIP-DILI2. Moreover, the United States
FDA encourages these programs and has issued a letter of support
for the further development and use of the biomarkers identified
by the SAFE-T Consortium (Food Drug Administration, 2016).
Nevertheless, up to date, DILI biomarker candidates are either
not liver specific, or they cannot differentiate between the causes
for liver damage and ultimately between the responsible drugs
(Andrade et al., 2009). To our knowledge, we are the first to report
on a combined technique which uses proteomics analysis of MH
cells to identify drug-specific biomarkers. Through analysis of
protein expression profiles of MH cells from different donors,
we found that patients suffering from Diclofenac-DILI cluster
away from healthy controls and patients with liver injury due
to other causes. Thus, differences in baseline protein expression
might reflect predisposition to develop Diclofenac-DILI, which
is known to affect only susceptible patients (Boelsterli, 2003).
Moreover, Diclofenac-treatment of MH cells from DicloDILI
patients lead to upregulation of a significant amount of proteins.
Pathway enrichment analysis revealed that many of these proteins
are involved in immune response and metabolism by cytochrome
P450 enzymes. This is in line with existing data, showing
that both mechanisms contribute to hepatocellular injury by
Diclofenac (Boelsterli, 2003). The same data set also showed
enrichment in cell adhesion molecules, such as ITGB3. This
suggests that ITGB3 plays an important role in inflammatory
response and liver regeneration upon injury through Diclofenac-
treatment. In support of this theory, our preliminary results
showed ITGB3 accumulation at inflammatory sites in the liver of
a DicloDILI patient, compared to one other ALI and one other
DILI subject. This indicates that ITGB3-expressing cells might
be recruited into the liver upon injury, which would also explain
their decrease in peripheral blood (Figure 4C).
A major challenge in the search for drug-specific DILI-
biomarkers is the rare frequency of events. Even in large
registries, iDILI cases adjudicated to the same drug rarely exceed
10 or 20 individuals. Thus, even a few false positives can cause
significant dilution and lead to disappointing results. In this
proof-of-concept study we could show that the combination
of novel techniques for diagnosis and sample analysis can
help to overcome major challenges in the iDILI setting: Even
few test subjects allow the identification of promising novel
markers. Taken altogether, this study provides evidence for
ITGB3 as potential biomarker for Diclofenac-induced DILI.
Although limited by a small sample cohort, ITGB3 meets all
of the criteria defined by EMA for DILI biomarkers (European
Medicines Agency, 2016). Furthermore, investigations to support
our findings are ongoing: currently, we could confirm the ITGB3
decrease in blood in three cases with DicloDILI. EMA requires
that the DILI biomarker provides an early or earlier diagnosis
compared to current standards. ITGB3 can be used as an early
1https://www.imi.europa.eu/projects-results/project-factsheets/safe-t
2https://www.imi.europa.eu/projects-results/project-factsheets/mip-dili
diagnostic marker, which specifically detects Diclofenac-DILI
from a small blood sample. ITGB3 can be as easily assessed as
liver enzymes, and in contrast, is able to identify the cause of
the liver damage. According to EMA, a DILI biomarker should
also have the ability to predict DILI outcome and monitor
disease progression. In this regard, ITGB3 expression correlated
inversely with progression/remission in two individual patients.
Additionally, the patient displaying the lowest ITGB3 values
was the one requiring a liver transplant, suggesting that ITGB3
might also be used for outcome prediction. The last criterion
of EMA refers to the ability of the biomarker to differentiate
between adaptors and patients which incur upon drug treatment.
ITGB3 was found to be upregulated only in Diclofenac-treated
MH cells from DicloDILI patients and not in healthy subjects
exposed to Diclofenac. Nevertheless, future investigations for the
analysis of initial liver enzyme elevations, followed by ALI or
adaption and correlations with ITGB3 expression are required.
As a current context of use we propose measurement of ITGB3
in whole blood derived from patients who present with ALI
and a history of Diclofenac intake. If ITGB3 is decreased,
this strongly points toward the diagnosis DILI by Diclofenac.
Further studies of ITGB3 expression and regulation shall
provide valuable insights into cellular mechanisms underlying
Diclofenac-DILI, thereby addressing a pressing challenge in the
field of iDILI characterization and prediction (Funk and Roth,
2017).
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